PRK Partners has advised Affimed on its successful divestment of AbCheck to Flagship Pioneering company Ampersand Biomedicines.
Affimed is a clinical-stage immuno-oncology company.
AbCheck is a Czech biotechnology company focusing on the discovery and development of human therapeutic antibodies.
According to PRK Partners, “through the transaction, AbCheck became a wholly-owned subsidiary of Ampersand Biomedicines, a Flagship Pioneering company.”
The PRK Partners team included Partner Monika Maskova and Co-Head of Corporate and M&A Milan Sivy.
PRK Partners did not respond to our inquiry on the matter.
